Blog cover image placeholder

Researchers Find New Way to Diagnose Potential for Alzheimer’s Disease

New method is less invasive and less costly

Memphis, TN, USA – Early diagnosis of Alzheimer’s disease has been shown to reduce cost and improve patient outcomes, but current diagnostic approaches can be invasive and costly. A recent study, published in the Journal of Alzheimer’s Disease, has found a novel way to identify a high potential for developing Alzheimer’s disease before symptoms occur. Ray Romano, PhD, RN, completed the research as part of his PhD in the Nursing Science Program at the University of Tennessee Health Science Center (UTHSC) College of Graduate Health Sciences. Dr. Romano conducted the research through the joint laboratory of Associate Professor Todd Monroe, PhD, RN, at The Ohio State University, who is also a graduate of the UTHSC Nursing Science PhD Program and Ronald Cowan, MD, PhD, who is the Chair of Psychiatry at UTHSC.

Dr. Romano said, “There is a real need to find ways to diagnose Alzheimer’s disease in the primary care setting where most patients first present with concerns for their memory.”

The research found that cognitively healthy people at increased genetic risk of late-onset Alzheimer’s disease showed significantly lower sensitivity to thermal pain but felt greater unpleasantness related to that pain when compared to people at lower risk of the disease. These results suggest that altered pain perception could potentially be used as a biomarker of late-onset Alzheimer’s disease before symptoms occur.

Previous research had identified a specific genetic allele, APOE4, as a marker associated with an increased incidence of developing late-onset Alzheimer’s disease. In his ground-breaking study, Dr. Romano was able to identify individuals who were cognitively healthy but had the APOE4 allele. He was then able to determine whether people with the APOE4 allele responded differently to experimentally-induced painful stimuli than did cognitively healthy individuals who did not have this allele.

Dr. Cowan noted, “This work also highlights the great strength of joint collaboration between nursing and psychiatry, which have been highly productive for our research programs.” The study included 49 cognitively healthy adults aged 30–89. Twelve of the subjects had the APOE4 allele, and 37 did not. They were assessed for group differences in pain thresholds and feelings of unpleasantness in response to experimentally-induced thermal pain stimuli. Dr. Romano believes that this is the first report of a connection of APOE4 allele status with an altered response in pain in a cognitively healthy sample of adults across the lifespan.

Use of this biomarker to identify people at risk of Alzheimer’s disease before the onset of serious symptoms would be much less invasive than other methods of Alzheimer’s diagnosis, which include lumbar punctures and positron emission topography (PET) scans. These are expensive tests that are not practical in primary care settings.

“In this exploratory study, Dr. Romano demonstrated that healthy adults with a specific gene for developing late-stage Alzheimer’s disease experience pain differently than people without the genetic marker,” Dr. Monroe said. “Next, we need to examine the brain’s pain systems to determine why this may be occurring. If future studies confirm these results, findings may eventually translate into earlier screening in people at risk of developing Alzheimer’s disease leading to more treatment options.”

Approximately 5.8 million people in the US live with Alzheimer’s disease – the sixth-leading cause of death in the country, according to the Alzheimer’s Association. It is estimated that 500,000 new cases of the disease are diagnosed in the US annually.


Full open access study: “Could Altered Evoked Pain Responsiveness Be a Phenotypic Biomarker for Alzheimer’s Disease Risk? A Cross-Sectional Analysis of Cognitively Healthy Individuals” by Raymond R. Romano, Michael A. Carter, Mary S. Dietrich, Ronald L. Cowan, Stephen P. Bruehl, and Todd B. Monroe (DOI: 10.3233/JAD-201293), published in the Journal of Alzheimer’s Disease, Volume 79, Issue 3 (February 2021). The article is freely available at:

For further information please contact Diana Murray, IOS Press (+1 7186405678 or To reach the authors for comment please contact Dr. Todd Monroe (+1 6149661655 or

About the Journal of Alzheimer’s Disease
Now in its 24th year of publication, the Journal of Alzheimer’s Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment, and psychology of Alzheimer’s disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease, and clinical trial outcomes. JAD has a Journal Impact Factor of 3.909 according to Journal Citation Reports (Clarivate, 2020). The journal is published by IOS Press.

About IOS Press
IOS Press is headquartered in Amsterdam with satellite offices in the USA, Germany, India and China and serves the information needs of scientific and medical communities worldwide. IOS Press now publishes more than 90 international peer-reviewed journals and about 70 book titles each year on subjects ranging from computer science, artificial intelligence, and engineering to medicine, neuroscience, and cancer research.